Pfizer Inc. (NYSE: PFE) lost around 0.30% on July 7 trading session; it opened trading at $35.52, lowering to $35.35. It hit a high at $35.77 and closed trading with an intraday trading volume of 22.903 Million.
In Friday’s session prices declined. In the past 52 weeks, PFE’s lowest traded price was $35.35, and its highest trading price was $54.93. Pfizer Inc. (NYSE: PFE) market capitalization is $200.578 Billion and $29.332 Million at press time.
PFE stock slipped more than 1.50% weekly and around 7.35% monthly. TradingView technical indicators suggest selling pressure although analysts’ ratings indicate buying and holding the stock for long-term profit.
The annual price target of Pfizer Inc. (NYSE: PFE) stock is $46.05, which is around 29.59% greater than the current trading prices.
According to TradingView, around 5.643 Billion shares of Pfizer Inc. are free-floating, and the remaining 2.281 Million shares are closely held by the company’s financial backers or the board of directors.
Recent News
Caribou Biosciences (NASDAQ: CRBU) informed on June 30 that Pfizer Inc. has completed a $25 Million equity investment in the company. After the announcement its stock surged over 38% in pre-market.
Caribou has a lot to prove with its phase 1 ANTLER study for CB-010, which has enrolled patients with relapsed or refractory B cell non-Hodgkin lymphoma.
Last year, just a few weeks after announcing a 100% overall response rate, the firm disclosed that 50% of patients reverted after receiving its top allogeneic CAR-T therapy within six months.
Pfizer Inc. (NYSE: PFE) Earnings & Revenue
In Q1 2023, Pfizer Inc. reported 10.09% more income than estimated revenue; as per the predicted figures, the company was expected to report $16.61 Billion in revenue, it reported $18.28 Billion.
Earning per share of company surged more than 24.98 percent in Q1 compared to the estimated figures.
Pfizer’s income is primarily generated from biopharma and other business activities. Moreover, it operates in the United States, Europe, Japan and numerous regions of Asia Pacific.
The revenue-to-profit conversion of Pfizer Inc. includes 62% of gross profit, 42% of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA), 37% of Earnings before interest and taxes (EBIT), and 31% of net income.
In the short term, the assets of Pfizer Inc. are $51.26 Billion, and liabilities are $42.14 Billion; similarly, in the long term, the company’s assets are $145.95 Billion, and liabilities are $59.15 Billion.
According to a recent report by Goldman Sachs, the global pharmaceutical sector has more than $700 Billion available for mergers, acquisitions, and investments.
Disclaimer
The views and opinions stated by the author, or any people named in this article, are for informational ideas only and do not establish financial, investment, or other advice. Investing in or trading crypto assets comes with a risk of financial loss.
Andrew is a blockchain developer who developed his interest in cryptocurrencies while his post-graduation. He is a keen observer of details and shares his passion for writing along with being a developer. His backend knowledge about blockchain helps him give a unique perspective to his writing
Source: https://www.thecoinrepublic.com/2023/07/09/pfe-stock-lost-over-1-80-post-caribou-biosciences-investment/